Focus: BioMarin is a mid-cap specialty pharmaceutical company focused on biologics for rare metabolic and genetic diseases. Founded in 1997 and publicly traded (NASDAQ: BMRN), it generates ~$2.4B in revenue with a diversified portfolio spanning rare disease, cardiovascular, oncology, and nephrology.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Recent layoff filing — 117 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow BioMarin Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from BioMarin Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product generating 35% of company revenue; PEGylated enzyme substitutes for deficient PAH in PKU patients and continues to drive corporate profitability.
Help build intelligence for BioMarin Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest revenue contributor; lysosomal enzyme replacement therapy for rare MPS IVA with established market presence and stable reimbursement.
Mature enzyme replacement therapy facing patent expiration; revenue declining as older product in portfolio faces competitive and exclusivity pressures.
Cofactor therapy activating residual PAH enzyme activity in PKU; complementary to PALYNZIQ for PKU treatment and provides near-term patent protection until 2033.
Hydrolytic lysosomal enzyme for rare MPS VI with declining revenue trajectory as market matures and generic/biosimilar pressure builds.
Innovative CNS-delivered enzyme therapy for rare pediatric neurodegenerative disease; demonstrates BioMarin's technical depth in challenging lysosomal enzyme delivery.
Rare genetic disorder therapy with extended patent protection (LOE 2042); represents newer generation portfolio and potential growth driver beyond traditional lysosomal diseases.
BioMarin Pharmaceutical Inc. Tokenized Stock (Ondo) price today, BMRNon to USD live price, marketcap and chart - CoinMarketCap
BioMarin Pharmaceutical Inc. Tokenized Stock (Ondo) price today, BMRNon to USD live price, marketcap and chart CoinMarketCap
GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin - KED Global
GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin KED Global
GC Biopharma and Hanmi sign $475m deal with BioMarin — Korea Herald - UA.NEWS
GC Biopharma and Hanmi sign $475m deal with BioMarin — Korea Herald UA.NEWS
GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin - The Korea Herald
GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin The Korea Herald
GC, Hanmi license Fabry disease drug to BioMarin in deal worth up to $475 million - Korea Biomedical Review
GC, Hanmi license Fabry disease drug to BioMarin in deal worth up to $475 million Korea Biomedical Review
GC Biopharma, Hanmi Pharm license Fabry disease drug to BioMarin in deal worth up to $475m - 헤럴드경제
GC Biopharma, Hanmi Pharm license Fabry disease drug to BioMarin in deal worth up to $475m 헤럴드경제
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
Recent large-scale layoff (117 employees) combined with historical patent cliff exposure and product concentration creates elevated risk of further organizational changes; new hires should assess role stability and team headcount trends closely.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo